Glutathione and cellular response of ACNU-resistant rat glioma sublines to drugs and radiation. 1991

Y Saito, and Y Nakada, and T Hotta, and T Mikami, and K Kurisu, and K Yamada, and K Kiya, and K Kawamoto, and T Uozumi
Department of Neurosurgery, Hiroshima University School of Medicine, Japan.

Three ACNU-resistant sublines (R1, R3 and R12) from rat glioma 9L cells showed cross-resistance to vinblastine, adriamycin, and VP-16. Among these, the R3 subline also acquired radioresistance under aerobic conditions. Total glutathione levels in these sublines were elevated 2- to 3-fold. Treatment of the cells with BSO, a specific inhibitor of GSH synthesis, resulted in decreased intracellular total glutathione levels in all 4 cell lines to about 10% of control levels. However, sensitivity to radiation or to chemicals did not change accordingly. Treatment of 9L cells with OTZ, a precursor of cysteine, resulted in a rise in intracellular GSH levels but it did not correlate with sensitivity to X-ray or to ACNU. These results suggest that, in terms of cellular sensitivity to radiation or ACNU, total glutathione level alone cannot serve as a predictive indicator.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008717 Methionine Sulfoximine Sulfoximine, Methionine
D011761 Pyrrolidonecarboxylic Acid A cyclized derivative of L-GLUTAMIC ACID. Elevated blood levels may be associated with problems of GLUTAMINE or GLUTATHIONE metabolism. 5-Oxoproline,Pidolic Acid,Pyroglutamic Acid,5-Ketoproline,5-Oxopyrrolidine-2-Carboxylic Acid,Magnesium Pidolate,Pyroglutamate,Pidolate, Magnesium
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004307 Dose-Response Relationship, Radiation The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation. Dose Response Relationship, Radiation,Dose-Response Relationships, Radiation,Radiation Dose-Response Relationship,Radiation Dose-Response Relationships,Relationship, Radiation Dose-Response,Relationships, Radiation Dose-Response
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell

Related Publications

Y Saito, and Y Nakada, and T Hotta, and T Mikami, and K Kurisu, and K Yamada, and K Kiya, and K Kawamoto, and T Uozumi
January 1987, Journal of neuro-oncology,
Y Saito, and Y Nakada, and T Hotta, and T Mikami, and K Kurisu, and K Yamada, and K Kiya, and K Kawamoto, and T Uozumi
August 1984, No shinkei geka. Neurological surgery,
Y Saito, and Y Nakada, and T Hotta, and T Mikami, and K Kurisu, and K Yamada, and K Kiya, and K Kawamoto, and T Uozumi
September 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Saito, and Y Nakada, and T Hotta, and T Mikami, and K Kurisu, and K Yamada, and K Kiya, and K Kawamoto, and T Uozumi
September 1992, Journal of neurosurgery,
Y Saito, and Y Nakada, and T Hotta, and T Mikami, and K Kurisu, and K Yamada, and K Kiya, and K Kawamoto, and T Uozumi
February 1987, No shinkei geka. Neurological surgery,
Y Saito, and Y Nakada, and T Hotta, and T Mikami, and K Kurisu, and K Yamada, and K Kiya, and K Kawamoto, and T Uozumi
November 1986, No to shinkei = Brain and nerve,
Y Saito, and Y Nakada, and T Hotta, and T Mikami, and K Kurisu, and K Yamada, and K Kiya, and K Kawamoto, and T Uozumi
January 1989, Drug metabolism reviews,
Y Saito, and Y Nakada, and T Hotta, and T Mikami, and K Kurisu, and K Yamada, and K Kiya, and K Kawamoto, and T Uozumi
October 1986, No shinkei geka. Neurological surgery,
Y Saito, and Y Nakada, and T Hotta, and T Mikami, and K Kurisu, and K Yamada, and K Kiya, and K Kawamoto, and T Uozumi
September 1993, Journal of neuro-oncology,
Y Saito, and Y Nakada, and T Hotta, and T Mikami, and K Kurisu, and K Yamada, and K Kiya, and K Kawamoto, and T Uozumi
March 1987, No shinkei geka. Neurological surgery,
Copied contents to your clipboard!